Trial Profile
An Open-label, Baseline-Controlled Study of the Safety and Efficacy of SeeMore (TM) (EVP 1001-1 Injection) in Heart Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2016
Price :
$35
*
At a glance
- Drugs EVP-1001-1 (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions
- Sponsors Eagle Vision Pharmaceutical Corporation
- 03 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Dec 2015 New trial record